The invention discloses the use of adenosine receptor antagonists, preferably A3 receptor antagonists, either alone or in combination with other agents for the treatment, prevention and/or management of diseases or disorders assocd. with overexpression of HIF-1 and/or increased HIF-1 activity (e.g., cancer, respiratory disease). The methods and compns. of the invention are particularly useful for preventing, treating, or ameliorating symptoms assocd. with a cancer, disease or disorder assocd. with hypoxia-inducible factor 1- (HIF-1) using the A3 receptor antagonists of the invention. The invention provides methods to inhibit the growth of tumors, particularly solid tumors and more particularly hypoxic tumors.
Enhancing treatment of cancer and HIF-1-mediated disorders with adenosine A3 receptor antagonists.
BOREA, Pier Andrea;BARALDI, Pier Giovanni;MERIGHI, Stefania;
2007
Abstract
The invention discloses the use of adenosine receptor antagonists, preferably A3 receptor antagonists, either alone or in combination with other agents for the treatment, prevention and/or management of diseases or disorders assocd. with overexpression of HIF-1 and/or increased HIF-1 activity (e.g., cancer, respiratory disease). The methods and compns. of the invention are particularly useful for preventing, treating, or ameliorating symptoms assocd. with a cancer, disease or disorder assocd. with hypoxia-inducible factor 1- (HIF-1) using the A3 receptor antagonists of the invention. The invention provides methods to inhibit the growth of tumors, particularly solid tumors and more particularly hypoxic tumors.I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
